PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne

MHEALTH

PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne

AustriaBelgiumBulgariaBosnia

HerzegovinaCyprus

Czech RepDenmarkEstoniaFinlandFrance

GermanyGreece

HungaryIreland

ItalyLuxembourg

MaltaNetherlands

PolandPortugalRomaniaSlovakiaSlovenia

SpainSweden

United KingdomCroatia

FYR MacedoniaNorwaySerbia

SwitzerlandTurkey

Pharmaceutical Group of European UnionMembers: Professional Bodies & Pharmacists’ Associations

2014: 32 Countries

PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne

PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne

PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne

PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne

Health Apps IMS study found that just 5 apps account for 15% of market,

and two of these are calorie counters;

Half of healthcare apps have only been downloaded 500 times;

The market is overwhelmingly dominated by lifestyle and wellness apps with very few diagnostic or even adherence apps;

There is no evidence [e.g. RCTs] that apps are effective;

There is an inverse relationship between smartphone use and healthcare need. This may change, but not for a long time.

PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne

Remote Monitoring

PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne

Remote Monitoring Strong evidence that telemonitoring offers no health

benefits over normal care;

Significant problems remain in the area of data transfer and poor adherence – in the NEJM study nearly half trial participants failed to adhere and 14% dropped out immediately;

Chain of Trust study showed that patients and health professionals considered the telehealth agenda to be manufacturer driven.

PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne

The Dilemmas of M Health M Health as a consumer appendage e.g wellness apps is at present a

highly marginal phenonemon in terms of overall health service provision, and likely to remain so for the foressable future;

‘Strong’ M Health (e.g. remote diagnosis and monitoring) needs to break into the mainstream of organised and funded health care. But this is likely to be based on efficiency imperatives, not on patient need, choice or empowerment.

The overall impact of M Health on the technologically incompetent, or averse is unknown, but a case can be made that it will increase health inequalities and undermine social capital.

PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne

PGEU GPUE Pharmaceutical Group of European UnionGroupement Pharmaceutique de l’Union Européenne

THANK YOUwww.pgeu.eu